Vir Biotechnology, Inc. (formerly Humabs BioMed AG)
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We are working on advancing antibody-based therapies that enhance the immune system’s ability to combat these potentially life-threatening diseases. Since 2025, Humabs BioMed AG (acquired by Vir Biotechnology in 2017) and Vir Biotechnology operate with a unified brand.
Date, time and room information
May 5, 15:30 - 15:45, room Montreal
Category
Clinical stage development company
Speaker information
| Name | Position | Institution |
|---|---|---|
| Filippo Riva | General Manager, Belllinzona site | Vir Biotechnology, Inc. (formerly Humabs BioMed AG) |
